• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma.

作者信息

Xu Shengshan, Lu Zhuming

机构信息

Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

出版信息

Asian J Surg. 2024 Aug 28. doi: 10.1016/j.asjsur.2024.08.056.

DOI:10.1016/j.asjsur.2024.08.056
PMID:39209650
Abstract
摘要

相似文献

1
The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma.LMNB2作为肺腺癌诊断和预后生物标志物的作用。
Asian J Surg. 2024 Aug 28. doi: 10.1016/j.asjsur.2024.08.056.
2
Kruppel like factor 16 promotes lung adenocarcinoma progression by upregulating lamin B2.Kruppel 样因子 16 通过上调核纤层蛋白 B2 促进肺腺癌的进展。
Bioengineered. 2022 Apr;13(4):9482-9494. doi: 10.1080/21655979.2022.2060780.
3
LMNB2 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.LMNB2 是肝细胞癌的预后生物标志物，并与免疫浸润相关。
IUBMB Life. 2020 Dec;72(12):2672-2685. doi: 10.1002/iub.2408. Epub 2020 Nov 19.
4
DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.DPYSL2 作为潜在的诊断和预后生物标志物与肺腺癌中的免疫浸润相关。
World J Surg Oncol. 2021 Sep 13;19(1):274. doi: 10.1186/s12957-021-02379-z.
5
ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.ADAR1 是一种预后生物标志物，与肺腺癌中的免疫浸润相关。
Cancer Med. 2023 Jul;12(13):14820-14832. doi: 10.1002/cam4.6044. Epub 2023 May 10.
6
SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.SNCA 与免疫浸润相关，可作为肺腺癌的预后生物标志物。
BMC Cancer. 2022 Apr 14;22(1):406. doi: 10.1186/s12885-022-09289-7.
7
TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.TYK2 是肺腺癌微环境中的一种预后生物标志物，并与免疫浸润相关。
Asia Pac J Clin Oncol. 2022 Apr;18(2):e129-e140. doi: 10.1111/ajco.13569. Epub 2021 Apr 14.
8
KIAA1199 Correlates With Tumor Microenvironment and Immune Infiltration in Lung Adenocarcinoma as a Potential Prognostic Biomarker.KIAA1199 与肺腺癌的肿瘤微环境和免疫浸润相关，可作为潜在的预后生物标志物。
Pathol Oncol Res. 2022 Nov 7;28:1610754. doi: 10.3389/pore.2022.1610754. eCollection 2022.
9
HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.HMMR 与免疫浸润物相关，并作为肺腺癌的预后生物标志物。
Comput Biol Med. 2022 Dec;151(Pt A):106213. doi: 10.1016/j.compbiomed.2022.106213. Epub 2022 Oct 23.
10
Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.全面分析线粒体转运相关基因 SFXN1 在肺腺癌中的预后和免疫特征。
BMC Cancer. 2024 Jan 17;24(1):94. doi: 10.1186/s12885-023-11646-z.

引用本文的文献

1
Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer.评估新辅助免疫疗法联合化疗治疗Ⅲa期非小细胞肺癌的疗效。
Sci Rep. 2025 Jul 31;15(1):28003. doi: 10.1038/s41598-025-13917-0.
2
Effect of the blood cells, inflammatory cytokines, antibodies, circulating metabolome, and immune cells on skin cancers: A bidirectional 2-sample Mendelian randomization study and mediation analysis.血细胞、炎性细胞因子、抗体、循环代谢组和免疫细胞对皮肤癌的影响：一项双向双样本孟德尔随机化研究及中介分析
Medicine (Baltimore). 2025 Jul 11;104(28):e43233. doi: 10.1097/MD.0000000000043233.
3
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations.
携带EGFR突变患者的T细胞免疫与EGFR-TKI耐药获得持续时间之间的相关性。
Cancer Immunol Immunother. 2025 Jul 12;74(8):265. doi: 10.1007/s00262-025-04113-0.
4
Liposomes, immune cells, and lung cancer subtypes: A bidirectional Mendelian randomization study.脂质体、免疫细胞与肺癌亚型：一项双向孟德尔随机化研究
Medicine (Baltimore). 2025 Jun 13;104(24):e42795. doi: 10.1097/MD.0000000000042795.
5
Small intestine metastasis from lung adenocarcinoma: A case report and review of literature.肺腺癌小肠转移：一例病例报告及文献复习
World J Gastrointest Surg. 2025 May 27;17(5):104049. doi: 10.4240/wjgs.v17.i5.104049.
6
LncRNA16 inhibits pyroptosis and promotes platinum resistance in non-small cell lung cancer by sponging miRNA1827 to regulate MBD3/GSDME expression.长链非编码RNA16通过海绵吸附微小RNA1827以调节MBD3/GSDME的表达，从而抑制非小细胞肺癌中的细胞焦亡并促进铂耐药。
Cancer Cell Int. 2025 May 24;25(1):192. doi: 10.1186/s12935-025-03812-z.
7
The association of immune-inflammation indices at multiple time points with treatment response and survival in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者多个时间点的免疫炎症指标与治疗反应和生存的相关性
World J Surg Oncol. 2025 May 16;23(1):195. doi: 10.1186/s12957-025-03833-y.
8
High-precision lung cancer subtype diagnosis on imbalanced exosomal data via Exo-LCClassifier.通过Exo-LCClassifier对不平衡外泌体数据进行高精度肺癌亚型诊断。
Front Genet. 2025 Apr 30;16:1583081. doi: 10.3389/fgene.2025.1583081. eCollection 2025.
9
Evaluating the safety and efficacy of combination immune checkpoint inhibitors and chemotherapy treatment in extensive-stage small cell lung cancer.评估联合免疫检查点抑制剂与化疗治疗广泛期小细胞肺癌的安全性和疗效。
Discov Oncol. 2025 May 5;16(1):670. doi: 10.1007/s12672-025-02440-3.
10
Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study.广泛期小细胞肺癌一线化疗联合免疫治疗的疗效分析及预后因素：一项真实世界研究
Sci Rep. 2025 Apr 16;15(1):13063. doi: 10.1038/s41598-025-98018-8.